Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Synthetic Lethality and Radiosensitization Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATM (Ataxia telangiectasia mutated) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Recombinant Kinase | ATM Active Kinase Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ATM Products |
| Gene Delivery | ATM Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression. |
View ATM Products |
| Benchmark Ab | Anti-ATM (Validation Standard) Recombinant positive control for western blot and target engagement. |
View ATM Products |
| Validator | ATM siRNA Set For knockdown verification and synthetic lethality screening. |
View ATM Products |
| Related Target A | ATR Synergistic DNA damage response (DDR) pathway and compensatory kinase. |
View ATR Products |
| Related Target B | PARP1 Primary synthetic lethality partner for homologous recombination deficiency (HRD). |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PIKK Family Off-target Profiling | Homolog panel proteins (ATR, DNA-PKcs, mTOR) strictly verified by mass spec and sequence analysis. |
| Kinase Domain Stability | Optimized expression systems yielding High Purity (>95%) active domains with precise Theoretical MW. |
| Lack of Robust Controls | Clinical Benchmark Antibodies included for reliable target engagement validation. |
| False Positives in Cell Assays | Sequence Verified siRNA included for highly specific knockdown specificity checks. |
Live ATM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ATM therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum chemotherapies to highly selective Small Molecule Inhibitors (SMIs) and Targeted Protein Degraders (PROTACs). As first-generation therapies reach the clinic primarily as radiosensitizers, the next wave of R&D is targeting synthetic lethality combinations, particularly pairing ATM inhibitors with PARP or ATR inhibitors in homologous recombination-deficient tumors. Furthermore, optimizing blood-brain barrier (BBB) penetration remains a dominant frontier for treating aggressive malignancies like glioblastoma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (SMI) | AstraZeneca, Merck KGaA | Glioblastoma, Solid Tumors | Selectivity Profiling (Need High-Purity PIKK Family Kinases) |
| PROTAC / Degrader | Preclinical Biotechs | Advanced Solid Tumors | Ternary Complex Validation (Need Sequence Verified Target Proteins) |
| Combination Therapy | Various (with PARP/ATR inhibitors) | Gastric, Colorectal Cancers | Pathway Interrogation (Need Knockdown siRNA Sets) |